Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2020. Available from www.ginasthma.org. Accessed May 23, 2022.
   Google Scholar
• Mukherjee M, Forero DF, Tran S, et al. Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena [published online ahead of print, 2020 May 22]. Eur Respir J. 2020;56(4):2000117. doi:10.1183/13993003.00117-2020
   PubMed Web of Science ®Google Scholar
• Penn RB. Mast cells in asthma: here I am, stuck in the middle with you. Eur Respir J. 2020;56(1):2001337. doi:10.1183/13993003.01337-2020
   PubMed Web of Science ®Google Scholar
• Hinks TS, Levine SJ, Brusselle GG. Treatment options in type-2 low asthma. Eur Respir J. 2020. doi:10.1183/13993003.00528-2020
   Web of Science ®Google Scholar
• Bradding P, Arthur G. Mast cells in asthma—state of the art. Clin Exp Allergy. 2016;46(2):194–263. doi:10.1111/cea.12675
   PubMed Web of Science ®Google Scholar
• Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med. 2011;183(3):299–309. doi:10.1164/rccm.201002-0295OC
   PubMed Web of Science ®Google Scholar
• Carter RJ, Bradding P. The role of mast cells in the structural alterations of the airways as a potential mechanism in the pathogenesis of severe asthma. Curr Pharm Des. 2011;17(7):685–698. doi:10.2174/138161211795428975
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699‐1705. doi:10.1056/NEJMoa012705
   PubMed Web of Science ®Google Scholar
• Maun HR, Jackman JK, Choy DF, et al. An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma [published correction appears in Cell. 2020 Jan 23;180(2):406]. Cell. 2019;179(2):417–431.e19. doi:10.1016/j.cell.2019.09.009
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258. doi:10.1371/journal.pone.0007258
   PubMed Web of Science ®Google Scholar
• Kardas G, Daszyńska-Kardas A, Marynowski M, Brząkalska O, Kuna P, Panek M. Role of Platelet-Derived Growth Factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target. Front Pharmacol. 2020;11:47. doi:10.3389/fphar.2020.00047
   PubMed Web of Science ®Google Scholar
• Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, DeClue AE, Reinero CR. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369‐374. doi:10.1159/000335122
   PubMed Web of Science ®Google Scholar
• Rhee CK, Kim JW, Park CK, et al. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol. 2011;155(3):243–251. doi:10.1159/000321261
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376(20):1911–1920. doi:10.1056/NEJMoa1613125
   PubMed Web of Science ®Google Scholar
• Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64(8):1194‐1201. doi:10.1111/j.1398-9995.2009.02122.x
   Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2014. Available from www.ginasthma.org. Accessed May 23, 2022.
   Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999a;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999b;115(5):1265–1270. doi:10.1378/chest.115.5.1265
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. doi:10.1164/rccm.200801-060ST
   PubMed Web of Science ®Google Scholar
• Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J. 2019;54(3):1900900. doi:10.1183/13993003.00900-2019
   PubMed Web of Science ®Google Scholar
• Global strategy for asthma management and prevention; 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed March 30, 2022.
   Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8(9):1375. doi:10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):CD010834. doi:10.1002/14651858.CD010834.pub3
   PubMed Web of Science ®Google Scholar